Clinical Trial Update: Safety and Efficacy Study of ONGLYZA (Saxagliptin) Under Conditions of Actual Use

View source ↗

Summary

The real-world safety and efficacy study of saxagliptin (Onglyza) in patients with Type 2 diabetes mellitus has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Onglyza (Saxagliptin)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes Mellitus | Status: TERMINATED